Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089834 | 0.94 | CNR1 (0.43) | CNR1DPP4SMN1; SMN2CYP3A4 | |
| SCHEMBL3078422 | 0.93 | ALDH1A1 (0.38) | DPP4SMN1; SMN2LMNATP53MAPT | |
| SCHEMBL3092256 | 0.91 | CNR1 (0.39) | CNR1DPP4MAPT | |
| SCHEMBL3090731 | 0.91 | P2RX7 (0.39) | DPP4SMN1; SMN2LMNATP53MAPT | |
| SCHEMBL3089159 | 0.91 | CNR1 (0.40) | CNR1DPP4SLC29A1LMNATP53 | |
| SCHEMBL3096527 | 0.90 | DPP4 (0.41) | DPP4KDM4ESMN1; SMN2SLC29A1 | |
| SCHEMBL3092355 | 0.88 | DPP4 (0.42) | CNR1DPP4SMN1; SMN2LMNATP53 | |
| SCHEMBL3604333 | 0.87 | KDM4C (0.44) | DPP4SMN1; SMN2LMNAP2RX7 | |
| SCHEMBL3088769 | 0.86 | CDK9 (0.39) | CNR1DPP4MAPT | |
| SCHEMBL3084453 | 0.86 | CNR1 (0.45) | CNR1DPP4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | claimed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007116092-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244177-A1 | ENZYME INHIBITORS | ACHE, BACE1, MAOA | CNR1 1272/4885DPP4 147/4885KDM4E 1761/4885 |
| US-20100234397-A1 | ENZYME INHIBITORS | ACHE, MAOA, BACE1 | CNR1 1107/4885DPP4 372/4885KDM4E 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.